Regulation Q; Regulatory Capital Rule: Risk-Based Capital Surcharges for Global Systemically Important Bank Holding Companies, 102908-102909 [2024-29981]
Download as PDF
102908
Federal Register / Vol. 89, No. 243 / Wednesday, December 18, 2024 / Notices
unit. Information submitted on the
substances within a category should be
reported for each individual chemical
structure, to the extent possible (i.e.,
known or reasonably ascertainable). If
the chemical identity of some of the
individual chemical structures are not
known or reasonably ascertainable by
the commenter, the information
associated with those chemical
substances may be reported as a group
of chemical structures (i.e., isomeric
mixture) or as the chemical category:
• 1-Hexadecanol, CASRN 36653–82–
4;
• 2-Ethylhexyl 2,3,4,5tetrabromobenzoate (TBB), CASRN
183658–27–7;
• Bis(2-Ethylhexyl)-3,4,5,6Tetrabromophthalate (TBPH), CASRN
26040–51–7;
• Bisphenol A, CASRN 80–05–7;
• Creosote, CASRN 8001–58–9;
• Di-n-octyl phthalate (DnOP),
CASRN 117–84–0;
• N-Nitroso-diphenylamine, CASRN
86–30–6;
• P,P′Oxybis(benzenesulfonylhydrazide),
CASRN 80–51–3;
• Tribromomethane, CASRN 75–25–
2;
• Triglycidyl isocyanurate, CASRN
2451–62–9;
• M-Xylene, CASRN 108–38–3;
• O-Xylene, CASRN 95–47–6;
• P-Xylene, CASRN 106–42–3;
• Antimony and Antimony
Compounds, Category;
• Arsenic and Arsenic Compounds,
Category;
• Cobalt and Cobalt Compounds,
Category;
• Lead and Lead Compounds,
Category;
• Long-chain chlorinated paraffins
(C18-20), Category;
• Medium-chain chlorinated paraffins
(C14-17), Category;
• Bisphenol S, CASRN 80–09–1;
• Hydrogen Fluoride, CASRN 7664–
39–3;
• N-(1,3-Dimethylbutyl)-N′-phenyl-pphenylenediamine (6PPD), CASRN 793–
24–8.
khammond on DSK9W7S144PROD with NOTICES
C. How will confidential business
information be protected?
A person seeking to protect from
disclosure as ‘‘confidential business
information’’ any information that
person submits under TSCA must assert
and substantiate a claim for protection
from disclosure concurrent with
submission of the information in
accordance with the requirements of
TSCA section 14 and 40 CFR 703, with
limited exceptions provided in the
statute. TSCA section 14(b) limits
VerDate Sep<11>2014
18:09 Dec 17, 2024
Jkt 265001
confidentiality protections for health
and safety studies and information from
such studies, however, and while EPA
considers confidential business
information when conducting its review
under 40 CFR 702.9(a), the Agency
encourages submitters to minimize
claims for protection from disclosure
wherever possible to maximize
transparency in EPA’s screening review.
More information on asserting and
submitting confidential business
information claims under TSCA can be
found at 40 CFR 703 and https://
www.epa.gov/tsca-cbi.
Authority: 15 U.S.C. 2601 et seq.
Dated: December 12, 2024.
Michal Freedhoff,
Assistant Administrator, Office of Chemical
Safety and Pollution Prevention.
[FR Doc. 2024–29829 Filed 12–17–24; 8:45 am]
BILLING CODE 6560–50–P
FEDERAL ELECTION COMMISSION
Sunshine Act Meetings
FEDERAL REGISTER CITATION NOTICE OF
PREVIOUS ANNOUNCEMENT: 89 FR 89012.
PREVIOUSLY ANNOUNCED TIME AND DATE OF
THE MEETING: Thursday, November 14,
2024 at 11:00 a.m., Hybrid Meeting:
1050 First Street NE, Washington, DC
(12th Floor) and virtual.
CHANGE IN THE MEETING: The November
14, 2024 Open Meeting was canceled.
CONTACT PERSON FOR MORE INFORMATION:
Judith Ingram, Press Officer. Telephone:
(202) 694–1220.
(Authority: Government in the Sunshine Act,
5 U.S.C. 552b)
Laura E. Sinram,
Secretary and Clerk of the Commission.
[FR Doc. 2024–30107 Filed 12–16–24; 11:15 am]
BILLING CODE 6715–01–P
FEDERAL RESERVE SYSTEM
[Docket No. OP–1863]
Regulation Q; Regulatory Capital Rule:
Risk-Based Capital Surcharges for
Global Systemically Important Bank
Holding Companies
Board of Governors of the
Federal Reserve System (Board).
ACTION: Notice.
AGENCY:
The Board is providing notice
of the 2024 aggregate global indicator
amounts, as required under the Board’s
rule regarding risk-based capital
surcharges for global systemically
important bank holding companies.
SUMMARY:
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
DATES:
December 18, 2024.
FOR FURTHER INFORMATION CONTACT:
Anna Lee Hewko, Associate Director,
(202) 250–1577, Brian Chernoff,
Manager, (202) 731–8914, Alexander
Jiron, Senior Financial Institution Policy
Analyst II, (202) 450–7350, or Aakash
Jani, Senior Financial Institution Policy
Analyst I, (202) 941–8305, Division of
Supervision and Regulation; or Jay
Schwarz, Deputy Associate General
Counsel, (202) 452–2970, Mark Buresh,
Senior Special Counsel, (202) 499–0261,
Jonah Kind, Senior Counsel, (202) 309–
5287, or David Imhoff, Senior Attorney
(202) 834–3222, Legal Division. Board of
Governors of the Federal Reserve
System, 20th and C NW, Washington,
DC 20551. For the hearing impaired and
users of Telecommunications Device for
the Deaf (TDD) and TTY–TRS, please
call 711 from any telephone, anywhere
in the United States.
SUPPLEMENTARY INFORMATION: The
Board’s framework for determining riskbased capital surcharges for global
systemically important bank holding
companies (GSIB surcharge rule)
establishes a methodology to identify
global systemically important bank
holding companies (GSIBs) in the
United States based on indicators that
are correlated with systemic
importance.1 Under the GSIB surcharge
rule, a firm must calculate its GSIB
score using a specific formula (method
1). Method 1 uses five equally weighted
categories that are correlated with
systemic importance—size,
interconnectedness, cross-jurisdictional
activity, substitutability, and
complexity—and subdivided into
twelve systemic indicators.
A firm divides its own measure of
each systemic indicator by an aggregate
global indicator amount. A firm’s
method 1 score is the sum of its
weighted systemic indicator scores
expressed in basis points. A firm that
calculates a method 1 score of 130 basis
points or more is identified as a GSIB
under the GSIB surcharge rule. The
GSIB surcharge for a firm is the higher
of the GSIB surcharge determined under
method 1 and a second method, method
2, which is calculated based on
measures of size, interconnectedness,
cross-jurisdictional activity, complexity,
and the firm’s reliance on short-term
wholesale funding.2
The aggregate global indicator
amounts used in the score calculation
1 See
12 CFR 217.402, 217.404.
2 uses similar inputs to those used in
method 1 but replaces the substitutability category
with a measure of a firm’s use of short-term
wholesale funding. In addition, method 2 is
calibrated differently from method 1. See 12 CFR
217.405.
2 Method
E:\FR\FM\18DEN1.SGM
18DEN1
102909
Federal Register / Vol. 89, No. 243 / Wednesday, December 18, 2024 / Notices
under method 1 are based on data
collected by the Basel Committee on
Banking Supervision (BCBS). The BCBS
amounts are determined based on the
sum of the systemic indicator amounts
as reported by the 75 largest U.S. and
foreign banking organizations as
measured by the BCBS, and any other
banking organization that the BCBS
includes in its sample total for that year.
The BCBS publicly releases these
amounts, denominated in euros, each
year.3 Pursuant to the GSIB surcharge
rule, the Board publishes the aggregate
global indicator amounts each year as
denominated in U.S. dollars using the
euro-dollar exchange rate provided by
the BCBS.4 Specifically, to determine
the 2024 aggregate global indicator
amounts, the Board uses the year-end
2023 euro-denominated indicator
amounts published by the BCBS and
multiplies each of the eurodenominated indicator amounts by
1.105, the euro to U.S. dollar spot
exchange rate on December 31, 2023.5
The aggregate global indicator
amounts expressed in U.S. dollars for
purposes of the 2024 method 1 score
calculation under § 217.404(b)(1)(i)(B) of
the GSIB surcharge rule are:
AGGREGATE GLOBAL INDICATOR AMOUNTS IN U.S. DOLLARS (USD) FOR 2024
Systemic indicator
Size ........................................................................
Interconnectedness ...............................................
Total exposures ...............................................................................
Intra-financial system assets ...........................................................
Intra-financial system liabilities ........................................................
Securities outstanding .....................................................................
Payments activity ............................................................................
Assets under custody ......................................................................
Underwritten transactions in debt and equity markets ...................
Notional amount of over-the-counter (OTC) derivatives .................
Trading and available-for-sale (AFS) securities ..............................
Level 3 assets .................................................................................
Cross-jurisdictional claims ...............................................................
Cross-jurisdictional liabilities ...........................................................
Substitutability ........................................................
Complexity .............................................................
Cross-jurisdictional activity ....................................
Authority: 12 U.S.C. 248(a), 321–338a,
481–486, 1462a, 1467a, 1818, 1828,
1831n, 1831o, 1831p–l, 1831w, 1835,
1844(b), 1851, 3904, 3906–3909, 4808,
5365, 5368, 5371.
By order of the Board of Governors of the
Federal Reserve System, acting through the
Director of Supervision and Regulation under
delegated authority.
Ann E. Misback,
Secretary of the Board.
[FR Doc. 2024–29981 Filed 12–17–24; 8:45 am]
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Notice of Meetings
Agency for Healthcare Research
and Quality (AHRQ), Department of
Health and Human Services (HHS).
ACTION: Notice of five AHRQ
subcommittee meetings.
AGENCY:
The subcommittees listed
below are part of AHRQ’s Health
Services Research Initial Review Group
(IRG) Committee. Grant applications are
SUMMARY:
khammond on DSK9W7S144PROD with NOTICES
Aggregate global
indicator amount
(in USD)
Category
3 The data used by the Board are available on the
BCBS website at https://www.bis.org/bcbs/gsib/
denominators.htm.
4 12 CFR 217.404(b)(1)(i)(B); see also 80 FR 49082,
49086–87 (August 14, 2015). In addition, the Board
VerDate Sep<11>2014
18:09 Dec 17, 2024
Jkt 265001
to be reviewed and discussed at these
meetings. Each subcommittee meeting
will be closed to the public.
DATES: See below for dates of meetings:
1. Healthcare Safety and Quality
Improvement Research (HSQR).
Date: February 5–6, 2025.
2. Healthcare Effectiveness and
Outcomes Research (HEOR).
Date: February 5–6, 2025.
3. Health System and Value Research
(HSVR).
Date: February 13–14, 2025.
4. Healthcare Research Training
(HCRT).
Date: February 27–28, 2025.
5. Healthcare Information Technology
Research (HITR).
Date: February 27–28, 2025.
ADDRESSES: Agency for Healthcare
Research and Quality (Virtual Review),
5600 Fishers Lane, Rockville, Maryland
20857.
FOR FURTHER INFORMATION CONTACT: (to
obtain a roster of members, agenda or
minutes of the non-confidential portions
of the meetings.)Jenny Griffith,
Committee Management Officer,
Division of Policy, Coordination and
Analysis, Office of Extramural Research
Education and Priority Populations,
Agency for Healthcare Research and
Quality (AHRQ), 5600 Fishers Lane,
maintains the GSIB Framework Denominators on its
website, available at https://
www.federalreserve.gov/supervisionreg/basel/
denominators.htm.
PO 00000
Frm 00058
Fmt 4703
Sfmt 9990
$115,205,051,188,518
11,253,226,663,114
11,388,383,441,235
19,247,590,871,111
3,527,103,136,881,927
219,479,268,261,988
7,962,804,019,185
733,514,990,056,729
4,278,831,961,372
803,127,442,989
28,416,427,492,687
23,524,643,383,930
Rockville, Maryland 20857, telephone
(301) 427–1557.
In
accordance with the Federal Advisory
Committee Act, 5 U.S.C. 1009(a)(2),
AHRQ announces meetings of the
above-listed scientific peer review
groups, which are subcommittees of
AHRQ’s Health Services Research Initial
Review Group Committee. The
subcommittee meetings will be closed to
the public in accordance with the
provisions set forth in 5 U.S.C. 1009(d),
5 U.S.C. 552b(c)(4), and 5 U.S.C.
552b(c)(6). The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Agenda items for these meetings are
subject to change as priorities dictate.
SUPPLEMENTARY INFORMATION:
Dated: December 12, 2024.
Marquita Cullom,
Associate Director.
[FR Doc. 2024–29969 Filed 12–17–24; 8:45 am]
BILLING CODE 4160–90–P
5 Foreign exchange rates provided by the BCBS.
Available at https://www.bis.org/bcbs/gsib/
reporting_instructions.htm.
E:\FR\FM\18DEN1.SGM
18DEN1
Agencies
[Federal Register Volume 89, Number 243 (Wednesday, December 18, 2024)]
[Notices]
[Pages 102908-102909]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-29981]
=======================================================================
-----------------------------------------------------------------------
FEDERAL RESERVE SYSTEM
[Docket No. OP-1863]
Regulation Q; Regulatory Capital Rule: Risk-Based Capital
Surcharges for Global Systemically Important Bank Holding Companies
AGENCY: Board of Governors of the Federal Reserve System (Board).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Board is providing notice of the 2024 aggregate global
indicator amounts, as required under the Board's rule regarding risk-
based capital surcharges for global systemically important bank holding
companies.
DATES: December 18, 2024.
FOR FURTHER INFORMATION CONTACT: Anna Lee Hewko, Associate Director,
(202) 250-1577, Brian Chernoff, Manager, (202) 731-8914, Alexander
Jiron, Senior Financial Institution Policy Analyst II, (202) 450-7350,
or Aakash Jani, Senior Financial Institution Policy Analyst I, (202)
941-8305, Division of Supervision and Regulation; or Jay Schwarz,
Deputy Associate General Counsel, (202) 452-2970, Mark Buresh, Senior
Special Counsel, (202) 499-0261, Jonah Kind, Senior Counsel, (202) 309-
5287, or David Imhoff, Senior Attorney (202) 834-3222, Legal Division.
Board of Governors of the Federal Reserve System, 20th and C NW,
Washington, DC 20551. For the hearing impaired and users of
Telecommunications Device for the Deaf (TDD) and TTY-TRS, please call
711 from any telephone, anywhere in the United States.
SUPPLEMENTARY INFORMATION: The Board's framework for determining risk-
based capital surcharges for global systemically important bank holding
companies (GSIB surcharge rule) establishes a methodology to identify
global systemically important bank holding companies (GSIBs) in the
United States based on indicators that are correlated with systemic
importance.\1\ Under the GSIB surcharge rule, a firm must calculate its
GSIB score using a specific formula (method 1). Method 1 uses five
equally weighted categories that are correlated with systemic
importance--size, interconnectedness, cross-jurisdictional activity,
substitutability, and complexity--and subdivided into twelve systemic
indicators.
---------------------------------------------------------------------------
\1\ See 12 CFR 217.402, 217.404.
---------------------------------------------------------------------------
A firm divides its own measure of each systemic indicator by an
aggregate global indicator amount. A firm's method 1 score is the sum
of its weighted systemic indicator scores expressed in basis points. A
firm that calculates a method 1 score of 130 basis points or more is
identified as a GSIB under the GSIB surcharge rule. The GSIB surcharge
for a firm is the higher of the GSIB surcharge determined under method
1 and a second method, method 2, which is calculated based on measures
of size, interconnectedness, cross-jurisdictional activity, complexity,
and the firm's reliance on short-term wholesale funding.\2\
---------------------------------------------------------------------------
\2\ Method 2 uses similar inputs to those used in method 1 but
replaces the substitutability category with a measure of a firm's
use of short-term wholesale funding. In addition, method 2 is
calibrated differently from method 1. See 12 CFR 217.405.
---------------------------------------------------------------------------
The aggregate global indicator amounts used in the score
calculation
[[Page 102909]]
under method 1 are based on data collected by the Basel Committee on
Banking Supervision (BCBS). The BCBS amounts are determined based on
the sum of the systemic indicator amounts as reported by the 75 largest
U.S. and foreign banking organizations as measured by the BCBS, and any
other banking organization that the BCBS includes in its sample total
for that year. The BCBS publicly releases these amounts, denominated in
euros, each year.\3\ Pursuant to the GSIB surcharge rule, the Board
publishes the aggregate global indicator amounts each year as
denominated in U.S. dollars using the euro-dollar exchange rate
provided by the BCBS.\4\ Specifically, to determine the 2024 aggregate
global indicator amounts, the Board uses the year-end 2023 euro-
denominated indicator amounts published by the BCBS and multiplies each
of the euro-denominated indicator amounts by 1.105, the euro to U.S.
dollar spot exchange rate on December 31, 2023.\5\
---------------------------------------------------------------------------
\3\ The data used by the Board are available on the BCBS website
at https://www.bis.org/bcbs/gsib/denominators.htm.
\4\ 12 CFR 217.404(b)(1)(i)(B); see also 80 FR 49082, 49086-87
(August 14, 2015). In addition, the Board maintains the GSIB
Framework Denominators on its website, available at https://www.federalreserve.gov/supervisionreg/basel/denominators.htm.
\5\ Foreign exchange rates provided by the BCBS. Available at
https://www.bis.org/bcbs/gsib/reporting_instructions.htm.
---------------------------------------------------------------------------
The aggregate global indicator amounts expressed in U.S. dollars
for purposes of the 2024 method 1 score calculation under Sec.
217.404(b)(1)(i)(B) of the GSIB surcharge rule are:
Aggregate Global Indicator Amounts in U.S. Dollars (USD) for 2024
----------------------------------------------------------------------------------------------------------------
Aggregate global
Category Systemic indicator indicator amount (in
USD)
----------------------------------------------------------------------------------------------------------------
Size........................................... Total exposures....................... $115,205,051,188,518
Interconnectedness............................. Intra-financial system assets......... 11,253,226,663,114
Intra-financial system liabilities.... 11,388,383,441,235
Securities outstanding................ 19,247,590,871,111
Substitutability............................... Payments activity..................... 3,527,103,136,881,927
Assets under custody.................. 219,479,268,261,988
Underwritten transactions in debt and 7,962,804,019,185
equity markets.
Complexity..................................... Notional amount of over-the-counter 733,514,990,056,729
(OTC) derivatives.
Trading and available-for-sale (AFS) 4,278,831,961,372
securities.
Level 3 assets........................ 803,127,442,989
Cross-jurisdictional activity.................. Cross-jurisdictional claims........... 28,416,427,492,687
Cross-jurisdictional liabilities...... 23,524,643,383,930
----------------------------------------------------------------------------------------------------------------
Authority: 12 U.S.C. 248(a), 321-338a, 481-486, 1462a, 1467a, 1818,
1828, 1831n, 1831o, 1831p-l, 1831w, 1835, 1844(b), 1851, 3904, 3906-
3909, 4808, 5365, 5368, 5371.
By order of the Board of Governors of the Federal Reserve
System, acting through the Director of Supervision and Regulation
under delegated authority.
Ann E. Misback,
Secretary of the Board.
[FR Doc. 2024-29981 Filed 12-17-24; 8:45 am]
BILLING CODE 6210-01-P